Concepedia

Christopher Karim

CK

Statistics

Publications

2

Citations

96

H-Index

2

Active since

2012

Affiliations

Novartis (United States)(Current)

Christopher Karim is an author at Novartis (United States) specializing in molecular oncology, prolactin function, and antibody-drug conjugate antibodies.

Publications per year

2012–2021

2

Publications

2

Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer

Jason S. Damiano, Katherine G. Rendahl, Christopher Karim et al. · Molecular Cancer Therapeutics · 2012 · 74 citations · Full text

, , +16

PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies

Qing Sheng, Joseph A. D’Alessio, Daniel L. Menezes et al. · Molecular Cancer Therapeutics · 2021 · 22 citations

, , +13

1–2 of 2